The estrogen puzzle in pulmonary arterial hypertension

Circulation

Volumn 126, Issue 9, 2012, Pages 1016-1019

  Paulin, Roxane ^a   Michelakis, Evangelos D ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,3',4,5' TETRAMETHOXYSTILBENE; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CYTOCHROME P450 1B1; CYTOCHROME P450 INHIBITOR; ESTRADIOL; ESTROGEN; RESVERATROL; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; GENE MUTATION; HEART RIGHT VENTRICLE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; ESTROGENS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; PULMONARY ARTERY;

EID: 84865489368     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.126474     Document Type: Review

References (28)

1. Loyd JE, Parker B Francis Lecture. Genetics and gene expression in pulmonary hypertension. Chest. 2002;121:46S-50S (Pubitemid 34248340)
2. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK, Levy PC, Reid LM, Vreim CE, Williams GW Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 1987;107:216-223. (Pubitemid 17137857)
3. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023-1030.
4. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon MD Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2009;137:376-387.
5. Tofovic SP Estrogens and development of pulmonary hypertension: interaction of estradiol metabolism and pulmonary vascular disease. J Cardiovasc Pharmacol. 2010;56:696-708.
6. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Cottin V, Degano B, Jais X, Montani D, Souza R, Simonneau G Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010; 122:156-163.
7. Farhat MY, Vargas R, Dingaan B, Ramwell PW In vitro effect of oestradiol on thymidine uptake in pulmonary vascular smooth muscle cell: role of the endothelium. Br J Pharmacol. 1992;107:679-683.
8. Farhat MY, Chen MF, Bhatti T, Iqbal A, Cathapermal S, Ramwell PW Protection by oestradiol against the development of cardiovascular changes associated with monocrotaline pulmonary hypertension in rats. Br J Pharmacol. 1993;110:719-723. (Pubitemid 23279284)
9. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003;144:3382-3398. (Pubitemid 36904414)
10. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci U S A 1996;93:9776-9781. (Pubitemid 26296685)
11. Swaneck GE, Fishman J Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci U S A 1988;85:7831-7835.
12. Zuckerman SH, Ahmari SE, Bryan-Poole N, Evans GF, Short L, Glasebrook AL Estriol: a potent regulator of TNF and IL-6 expression in a murine model of endotoxemia. Inflammation. 1996;20:581-597.
13. Tofovic SP, Zhang X, Jackson EK, Zhu H, Petrusevska G 2-methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogen-deficient rats. Vascul Pharmacol. 2009; 51:190-197.
14. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF Cancer Cell. 2003;3:363-375. (Pubitemid 38340305)
15. Yue TL, Wang X, Louden CS, Gupta S, Pillarisetti K, Gu JL, Hart TK, Lysko PG, Feuerstein GZ 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol Pharmacol. 1997;51:951-962. (Pubitemid 27249128)
16. Tofovic SP, Zhang X, Zhu H, Jackson EK, Rafikova O, Petrusevska G 2-Ethoxyestradiol is antimitogenic and attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling. Vascul Pharmacol. 2008;48:174-183.
17. Shimada T, Watanabe J, Kawajiri K, Sutter TR, Guengerich FP, Gillam EM, Inoue K Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999;20:1607-1613. (Pubitemid 29385452)
18. Economopoulos KP, Sergentanis TN Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2010;122:545-551.
19. West J, Cogan J, Geraci M, Robinson L, Newman J, Phillips JA, Lane K, Meyrick B, Loyd J Gene expression in BMPR2 mutation carriers with and without evidence of pulmonary arterial hypertension suggests pathways relevant to disease penetrance. BMC Med Genomics. 2008;1:45.
20. Austin ED, Cogan JD, West JD, Hedges LK, Hamid R, Dawson EP, Wheeler LA, Parl FF, Loyd JE, Phillips JA III Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J 2009;34:1093-1099.
21. White K, Johansen AK, Nilsen M, Ciuclan L, Wallace E, Paton L, Campbell A, Morecroft I, Loughlin L, McClure JD, Thomas M, Mair KM, MacLean MR Activity of the estrogen-metabolising enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension. Circulation. 2012;126:1087-1098.
22. Felty Q, Roy D Estrogen, mitochondria, and growth of cancer and non-cancer cells. J Carcinog. 2005;4:1.
23. Dromparis P, Sutendra G, Michelakis ED The role of mitochondria in pulmonary vascular remodeling. J Mol Med (Berl). 2010;88:1003-1010.
24. Csiszar A, Labinskyy N, Olson S, Pinto JT, Gupte S, Wu JM, Hu F, Ballabh P, Podlutsky A, Losonczy G, de Cabo R, Mathew R, Wolin MS, Ungvari Z Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension. 2009;54:668-675.
25. Park H, Aiyar SE, Fan P, Wang J, Yue W, Okouneva T, Cox C, Jordan MA, Demers L, Cho H, Kim S, Song RX, Santen RJ Effects of tetramethoxystilbene on hormone-resistant breast cancer cells: biological and biochemical mechanisms of action. Cancer Res. 2007;67:5717-5726. (Pubitemid 46985004)
26. Champion HC, Michelakis ED, Hassoun PM Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation. 2009;120:992-1007.
27. Kawut SM, Al-Naamani N, Agerstrand C, Rosenzweig EB, Rowan C, Barst RJ, Bergmann S, Horn EM Determinants of right ventricular ejection fraction in pulmonary arterial hypertension. Chest. 2009;135: 752-759.
28. Tandri H, Daya SK, Nasir K, Bomma C, Lima JA, Calkins H, Bluemke DA Normal reference values for the adult right ventricle by magnetic resonance imaging. Am J Cardiol. 2006;98:1660-1664. (Pubitemid 44827979)